There are a number of risk factors associated with the development of inflammatory bowel disease (IBD). These include being younger in age, being Caucasian or of Ashkenazi Jewish descent,…
Dr. Cecilia Chung and associates at the Vanderbilt University’s Medical Center conducted a study published recently in MedPage Today. Results showed that patients who had inflammatory disorders, as well…
What happens when you treat your condition, but the medication isn’t effective? Sometimes, other approved medications are beneficial for patient use, but other times, there are no approved medications.…
In the past, filgotinib (Jyseleca) has largely been used to treat patients with rheumatoid arthritis (RA). However, researchers hypothesized that the treatment could be beneficial in other indications. Following…
Have you ever heard of a biomarker? In short, a biomarker, or biological marker, is some sort of objective measure which can tell you something about your health or health…
When it comes to the diagnostic process, many refer to their journey as a "diagnostic odyssey." For those with rare or underserved conditions, diagnosis often requires months - or even…
From July 2-3 and 8-10, 2021, the European Crohn's and Colitis Organisation (ECCO) held its 2021 virtual Annual Congress (ECCO'21). During the Congress, many discussed new research and trends…
Clinical trials are important research tools to help understand the safety, efficacy, and tolerability of potential treatments. According to a news release from July 19, 2021, biotechnology company Prometheus Biosciences,…
Towards the end of June 2021, biopharmaceutical company AbbVie shared that Upadacitinib (RINVOQ) reached both its primary and all secondary endpoints in a Phase 3 maintenance study evaluating the therapy…
According to a story from Sano Genetics, Sano Genetics, BenevolentAI, C4X Discovery, and Patients Know Best expect only the most from their novel collaboration. Together, they are pooling top expertise…
A Phase 3 study of upadacitinib, an ulcerative colitis treatment, met both its primary and secondary endpoints, according to an announcement from AbbVie. The trial, titled U-ACCOMPLISH, saw a third…
Since its inception, biopharmaceutical company Reistone Biopharma Co. Ltd. ("Reistone") has worked to develop treatment options for patients with immuno-inflammatory and autoimmune conditions. Most recently, their drug candidate SHR0302,…
In a news release from biopharmaceutical company Bristol Myers Squibb, the company shared that the FDA accepted its supplemental New Drug Application (sNDA). Because the sNDA was submitted alongside…
As reported in EMJ Reviews, the world is on alert, being told to wash their hands and keep distance amidst the COVID-19 pandemic. However, patients with inflammatory bowel disease (IBD)…
Landos Biopharma has recently released data from their Phase 2 trial of BT-11, a treatment for ulcerative colitis. The results were positive, making this therapy a possible viable treatment for…
According Newswise, in a new study first published in Gastroenterology, researchers at Cedars-Sinai have identified a set of genes, made up of rare genetic deviations and more common genetic patterns,…
Earlier this month, biopharmaceutical company Applied Molecular Transport (AMT) announced the publication of its preclinical data in the Journal of Immunology. You can find the published article here. Within the study,…
Recently, Docbot, Inc. ("Docbot") announced results from a study performed on Ultivision. Altogether, Docbot's mission has been to create artificial intelligence (AI) technologies that can be applied within a healthcare…
Takeda Pharmaceuticals has recently announced the results from their open-label extension study, titled VISIBLE, which evaluates Entyvio as a treatment for ulcerative colitis. According to BioSpace, these results maintain the…
According to a story from Pharma Advancement, Bristol Myers Squibb recently announced encouraging findings from a phase 3 clinical trial. This study was testing its drug ozanimod (marketed as Zeposia)…
As reported in BioSpace; trials for an oral treatment to treat inflammatory bowel disease (IBD) by Morphic Therapeutics has just dosed their first healthy subjects in the Phase 1 trial.…
Recently, IVX Health announced the opening of three new Tampa-based infusion centers to treat patients with chronic conditions. Currently, IVX Health, who describes themselves as "[providing] biologic injections and infusions…
by Danielle Bradshaw from In The Cloud Copy Healthy and diseased colon cells were collected and compared to each other in a recent study to discover why inflammatory bowel disease…
Altogether, there are many foods that promote your health, provide protection against disease, and improve bodily function. According to researchers, there is one that we should be paying more…
Celltrion Healthcare has just announced positive progress for extending the authorization for the subcutaneous (SC) form of Remsima to five more autoimmune conditions. These are- Psoriatic arthritis Ankylosing spondylitis (AS)…
© Copyright Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
